CART-19 cells

CART-19 cells are autologous or allogeneic T lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) specific for the CD19 antigen. The process involves collecting a patient's (or donor's) T cells, modifying them in the laboratory to express a synthetic receptor that recognizes and binds to the CD19 protein found on B-cell malignancies, expanding these modified cells ex vivo, and then infusing them back into the patient. Upon encountering CD19-expressing cancerous B-cells in the body, these engineered T-cells become activated and exert cytotoxic effects leading to targeted destruction of malignant B-cells. This therapy is primarily used for refractory or relapsed B-cell hematologic malignancies such as acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and various types of non-Hodgkin lymphoma including diffuse large B-cell lymphoma (DLBCL). Multiple generations of CART-19 constructs exist with varying co-stimulatory domains to enhance efficacy and persistence[3][9].

Other names

CD19-targeted chimeric antigen receptor T cellsCD-19-targeted chimeric antigen receptor T cellsCD 19-targeted chimeric antigen receptor T cellsanti-CD19 CAR-T cellsanti-CD-19 CAR-T cellsanti-CD 19 CAR-T cells